COMMUNIQUÉS West-GlobeNewswire

Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
24/09/2026
RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
24/09/2026
TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026 [...]
Buckingham Psychiatry Welcomes Psychologist Dr. Sophie Buinewicz
24/09/2026
The Bucks County-Based Mental Health Practice Introduces a Licensed Clinical Psychologist to Its Team DOYLESTOWN, Pa. and LAMBERTVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Buckingham Psychiatry, serving patients in [...]
Spectral AI Announces Upcoming Presentation at ACS Clinical Congress 2026 Highlighting the Use of Artificial Intelligence and Multi-Spectral Imaging in the Assessment of Burn Wounds
24/09/2026
DALLAS, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]
NANOBIOTIX fait le point sur ses activités et ses résultats financiers du premier semestre 2026
24/09/2026
Résultats préliminaires prometteurs issus de l’analyse complète des cohortes dans les parties escalade et expansion de dose d’une étude achevée de phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints d’un [...]
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
24/09/2026
Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non [...]
Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D. to Its Board of Directors
24/09/2026
WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli [...]
UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. to Its Board of Directors
24/09/2026
WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli [...]
CORRECTION – Free Family Fun Night in Cedar Park: Ally Medical ER Ribbon Cutting
24/09/2026
Ally Medical ER Cedar Park hosts an evening of free food, drinks, giveaways, and kid-friendly games on October 1st. CEDAR PARK, Texas, Sept. 24, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline [...]
Eurobio Scientific: Results for the first semester of fiscal year 2026
24/09/2026
RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2026 Revenue up 4.5% to 84.5 M€ Proprietary products account for 37% of revenue 46% of revenue generated outside France Free cash flow of €4 million after investments Net [...]
Eurobio Scientific: Résultat du 1er semestre 2026
24/09/2026
RESULTAT DU 1 ER SEMESTRE 2026 Chiffre d’affaires en croissance de 4,5% à 84,5 M€ les produits propriétaires atteignent 37% du CA la part du CA hors France est de 46% Flux de trésorerie disponible de 4 M€ après [...]
SK pharmteco lance un kit de catalyseurs destiné à rationaliser le développement des réactions catalytiques et leur mise à l’échelle en fabrication continue
24/09/2026
Cette nouvelle offre structurée vise à assurer la continuité entre le criblage des catalyseurs, l’optimisation des procédés et la fabrication en flux continu à l’échelle commerciale pour les matières premières [...]
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
24/09/2026
SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones [...]
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
24/09/2026
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to [...]
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
24/09/2026
In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3- [...]
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
24/09/2026
Fort Lee, NJ, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the [...]
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
24/09/2026
Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic function SOUTH SAN FRANCISCO and [...]
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
24/09/2026
New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer Findings are expected to inform a refined Phase 3 [...]
Primmune Therapeutics Announces Enrollment Milestone in Phase 2 INFLECTION–003 Study of Polvitolimod HCl in Neoadjuvant Melanoma
24/09/2026
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics , a biotech company harnessing the power of the innate and adaptive immune system, today announced the enrollment of the second patient in its Phase 2 [...]

Pages